HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth

Retrovirology. 2018 Nov 26;15(1):74. doi: 10.1186/s12977-018-0457-7.

Abstract

Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutralizing antibodies (bNAbs) to protect against infection to date. The high antigenic diversity and dense N-linked glycan armor, which covers nearly the entire HIV-1 envelope protein (Env), are major roadblocks for the development of bNAbs by vaccination. In addition, the naive human antibody repertoire features a low frequency of exceptionally long heavy chain complementary determining regions (CDRH3s), which is a typical characteristic that many HIV-1 bNAbs use to penetrate the glycan armor. Native-like Env trimer immunogens can induce potent but strain-specific neutralizing antibody responses in animal models but how to overcome the many obstacles towards the development of bNAbs remains a challenge. Here, we review recent HIV-1 Env immunization studies and discuss strategies to guide strain-specific antibody responses towards neutralization breadth.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / immunology
  • Animals
  • Antibodies, Neutralizing / immunology*
  • Antibody Formation
  • Antigenic Variation / immunology*
  • Epitopes / immunology
  • HIV Antibodies / immunology*
  • HIV Envelope Protein gp120 / immunology
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV-1
  • Humans
  • Immunization
  • Mice
  • env Gene Products, Human Immunodeficiency Virus / immunology

Substances

  • AIDS Vaccines
  • Antibodies, Neutralizing
  • Epitopes
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • env Gene Products, Human Immunodeficiency Virus